Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... YORK, July 28 Fred Alger Management, Inc. ... hiring of David,Farhadi, M.D. as Vice President, Senior ... on the biotechnology and,pharmaceutical industries., David received ... of,Medicine where he was Chief Medical Resident. While ...
... high octane fuel just become obsolete? EnviroChip™ white papers show ... gallon without sacrificing performance or damaging your engine. , ... ... by Advanced Bio Technologies indicate that EnviroChip™, a revolutionary fuel harmonizing ...
... the University of Pennsylvania have created a one-step, ... patterns or motifs with adjustable features, size and ... Researchers took advantage of the elastic instability of ... PDMS. When exposed to a solvent, circular ...
Cached Biology Technology:David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 3
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... depends on peaceful coexistence with a swarm of microbial ... to energy to protection from disease. Now, with the ... create a predator-fooling light organ and a fish that uses ... a flashlight to illuminate the dark nooks of the reefs ...
... Gokhale has created a compound in his lab in India ... the molecule hits four of the bacterium,s crucial metabolic pathways ... ,The problem is that Gokhale,s compound will not work ... work, he has been knocking on the doors of pharmaceutical ...
... the Strait of Juan de Fuca, which separates Washington ... spot" for toxic harmful algal blooms affecting the Washington ... under certain conditions, toxic algal cells from an offshore ... areas, where they may trigger harmful algal blooms that ...
Cached Biology News:Single gene lets bacteria jump from host to host 2Single gene lets bacteria jump from host to host 3In India: A search for more effective tuberculosis drugs 2In India: A search for more effective tuberculosis drugs 3'Hot spot' for toxic harmful algal blooms discovered off Washington coast 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Shimadzus GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, ... of the GCMS-QP2010 Plus, offers high ... with an excellent performance-to-cost ratio. Like ... patented constant linear velocity for optimum ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... The Precision XS uniquely combines a ... head and an 8-channel bulk reagent dispenser ... addition to transfers using disposable pipette tips, ... resistant bulk reagent dispenser is available for ...
Biology Products: